These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12397691)

  • 41. Eplerenone suppresses neointima after coronary stenting in pigs: could it be extrapolated to stent restenosis in humans?
    Celik T; Iyisoy A; Kursaklioglu H; Isik E
    Int J Cardiol; 2007 Jan; 115(1):97-8; author reply 99-100. PubMed ID: 16797750
    [No Abstract]   [Full Text] [Related]  

  • 42. Prevention of restenosis future directions.
    Bauters C; Van Belle E; Meurice T; Letourneau T; Lablanche JM; Bertrand ME
    Trends Cardiovasc Med; 1997 Apr; 7(3):90-4. PubMed ID: 21235870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel gene silencer pyrrole-imidazole polyamide targeting lectin-like oxidized low-density lipoprotein receptor-1 attenuates restenosis of the artery after injury.
    Yao EH; Fukuda N; Ueno T; Matsuda H; Matsumoto K; Nagase H; Matsumoto Y; Takasaka A; Serie K; Sugiyama H; Sawamura T
    Hypertension; 2008 Jul; 52(1):86-92. PubMed ID: 18519843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beneficial effects of NO-releasing derivative of flurbiprofen (HCT-1026) in rat model of vascular injury and restenosis.
    Maffia P; Ianaro A; Sorrentino R; Lippolis L; Maiello FM; del Soldato P; Ialenti A; Cirino G
    Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):263-7. PubMed ID: 11834526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of restenosis with antioxidants: mechanisms and implications.
    Tardif JC; Grégoire J; L'Allier PL
    Am J Cardiovasc Drugs; 2002; 2(5):323-34. PubMed ID: 14727962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation.
    Rakugi H; Wang DS; Dzau VJ; Pratt RE
    Circulation; 1994 Jul; 90(1):449-55. PubMed ID: 7517799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coronary atherosclerosis and interventions: pathological sequences and restenosis.
    Yutani C; Imakita M; Ishibashi-Ueda H; Tsukamoto Y; Nishida N; Ikeda Y
    Pathol Int; 1999 Apr; 49(4):273-90. PubMed ID: 10365846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological approaches to the prevention of restenosis after coronary angioplasty.
    Hamon M; Lécluse E; Monassier JP; Grollier G; Potier JC
    Drugs Aging; 1998 Oct; 13(4):291-301. PubMed ID: 9805210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Irreversible electroporation attenuates neointimal formation after angioplasty.
    Maor E; Ivorra A; Leor J; Rubinsky B
    IEEE Trans Biomed Eng; 2008 Sep; 55(9):2268-74. PubMed ID: 18713696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Imitative restenosis after percutaneous transluminal coronary angioplasty prevented by buyang huanwu decoction in rabbits].
    Hou C; He Q; Li S
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2001 May; 21(5):359-63. PubMed ID: 12577422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Images in cardiovascular medicine. In-stent neointimal hyperplasia with 16-row multislice computed tomography coronary angiography.
    Mollet NR; Cademartiri F
    Circulation; 2004 Nov; 110(21):e514. PubMed ID: 15557383
    [No Abstract]   [Full Text] [Related]  

  • 52. [Clinical trials of restenosis after PTCA and QOL of patients after PTCA].
    Okamoto S; Nakano T
    Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):869-73. PubMed ID: 12436630
    [No Abstract]   [Full Text] [Related]  

  • 53. Plasminogen activator inhibitor-1 and restenosis.
    Garg N; Fay WP
    Curr Drug Targets; 2007 Sep; 8(9):1003-6. PubMed ID: 17896951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting.
    Kiernan TJ; Yan BP; Cruz-Gonzalez I; Cubeddu RJ; Caldera A; Kiernan GD; Gupta V
    Cardiovasc Hematol Agents Med Chem; 2008 Apr; 6(2):116-24. PubMed ID: 18473776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renin-angiotensin system intervention to prevent in-stent restenosis: an unclosed chapter.
    Langeveld B; Roks AJ; Tio RA; Voors AA; Zijlstra F; van Gilst WH
    J Cardiovasc Pharmacol; 2005 Jan; 45(1):88-98. PubMed ID: 15613985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stent implantation in coronary porcine arteries is associated with early activation of TNFalpha and TNFalpha receptor II expression.
    Hadjadj S; Cloutier I; Geoffroy P; Tanguay JF
    Atherosclerosis; 2007 May; 192(1):25-32. PubMed ID: 16857205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures.
    Landzberg BR; Frishman WH; Lerrick K
    Prog Cardiovasc Dis; 1997; 39(4):361-98. PubMed ID: 9050821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insights into vascular pathology after intracoronary brachytherapy.
    Bauriedel G; Skowasch D; Jabs A; Dinkelbach S; Andrié R; Schiele TM; Lüderitz B
    Z Kardiol; 2002; 91 Suppl 3():1-9. PubMed ID: 12641009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Effect of Angiotensin Receptor Blockers on In-Stent Restenosis After Stent Implantation: A Meta-Analysis.
    Zhao C; Hou K; Cao L; Wang J
    Heart Lung Circ; 2024 Apr; 33(4):486-492. PubMed ID: 38423849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renin-angiotensin system inhibitors in patients with coronary artery disease who have undergone percutaneous coronary intervention.
    Xiao-Dong Z; Fei-Fei L; Zhan-Peng W; Xin-Xue L; Zhi-Min D
    Ther Adv Cardiovasc Dis; 2016 Jun; 10(3):172-7. PubMed ID: 27185017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.